

References

- [1] Cancer Research UK. Skin cancer statistics. Tech. Rep. (2016).
- [2] American Cancer Society. Cancer Facts & Figures 2018. Tech. Rep. (2018).
- [3] Cancer Research UK. Melanoma skin cancer survival statistics, accessed on June 21st,2019. (2016).
- [4] Urteaga B., O. & Pack, G. T. On the antiquity of melanoma. *Cancer* **19**, 607–610 (1966).
- [5] Lane-Brown, M. & Roxanas, M. G. Laennec’s melanosis: The first published description of metastatic melanoma. *Australasian Journal of Dermatology* **58**, 234–235 (2017).
- [6] Norris, W. Case of Fungoid Disease. *Edinburgh medical and surgical journal* (1820).
- [7] Lynch, H. T., Fritchot, B. C. & Lynch, J. F. Familial atypical multiple mole-melanoma syndrome. *Journal of Medical Genetics* **15**, 352–356 (1978).
- [8] Lancaster, H. O. Some geographical aspects of the mortality from melanoma in Europeans. *Medical Journal of Australia* **1**, 1082–1087 (1956).
- [9] Clark, W. H., From, L., Bernardino, E. A. & Mihm, M. C. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. *Cancer research* **29**, 705–27 (1969).
- [10] Breslow, A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. *Annals of surgery* (1970).
- [11] Miller, A. J. & Mihm, M. C. Melanoma. *New England Journal of Medicine* **355**, 51–65 (2006).

- [12] Shimizu, K., Goldfarb, M., Perucho, M. & Wigler, M. Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. *Proceedings of the National Academy of Sciences* **80**, 383–387 (1983).
- [13] Padua, R. A., Barrass, N. & Currie, G. A. A novel transforming gene in a human malignant melanoma cell line. *Nature* (1984).
- [14] Muñoz-Couselo, E., Adelantado, E. Z., Ortiz, C., García, J. S. & Perez-Garcia, J. NRAS-mutant melanoma: Current challenges and future prospect (2017).
- [15] Davies, H. *et al.* Mutations of the BRAF gene in human cancer. *Nature* **417**, 949–954 (2002).
- [16] Huebner, K. *et al.* Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human. *Proceedings of the National Academy of Sciences* **83**, 3934–3938 (1986).
- [17] Ikawa, S. *et al.* B-raf, a new member of the raf family, is activated by DNA rearrangement. *Molecular and cellular biology* (1988).
- [18] Rapp, U. R. *et al.* Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. *Proceedings of the National Academy of Sciences of the United States of America* (1983).
- [19] Ascierto, P. A. *et al.* The role of BRAF V600 mutation in melanoma. *Journal of Translational Medicine* **10**, 85 (2012).
- [20] The Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. *Cell* **161**, 1681–1696 (2015).
- [21] Viros, A. *et al.* Improving melanoma classification by integrating genetic and morphologic features. *PLoS Medicine* (2008).
- [22] Valverde, P., Healy, E., Jackson, I., Rees, J. L. & Thody, A. J. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. *Nature genetics* **11**, 328–30 (1995).
- [23] Healy, E. *et al.* Melanocortin-1-receptor gene and sun sensitivity in individuals without red hair. *Lancet (London, England)* **355**, 1072–3 (2000).

- [24] Robles-Espinoza, C. D. *et al.* Germline MC1R status influences somatic mutation burden in melanoma. *Nature Communications* (2016).
- [25] Kamb, A. *et al.* Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. *Nature genetics* **8**, 23–6 (1994).
- [26] Hussussian, C. J. *et al.* Germline p16 mutations in familial melanoma. *Nature Genetics* **8**, 15–21 (1994).
- [27] Goldstein, A. M. *et al.* Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. *Journal of medical genetics* **44**, 99–106 (2007).
- [28] Cichorek, M., Wachulska, M., Stasiewicz, A. & Tymińska, A. Skin melanocytes: Biology and development. *Postepy Dermatologii i Alergologii* (2013).
- [29] Lin, J. Y. & Fisher, D. E. Melanocyte biology and skin pigmentation (2007).
- [30] Bharti, K., Miller, S. S. & Arnheiter, H. The new paradigm: Retinal pigment epithelium cells generated from embryonic or induced pluripotent stem cells (2011).
- [31] Plonka, P. M. *et al.* What are melanocytes really doing all day long...? *Experimental dermatology* **18**, 799–819 (2009).
- [32] Brenner, M. & Hearing, V. J. The protective role of melanin against UV damage in human skin. *Photochemistry and photobiology* **84**, 539–49 (2008).
- [33] Geremia, E. *et al.* Eumelanins as free radicals trap and superoxide dismutase activities in Amphibia. *Comparative Biochemistry and Physiology – Part B: Biochemistry and* (1984).
- [34] Nofsinger, J. B., Liu, Y. & Simon, J. D. Aggregation of eumelanin mitigates photogeneration of reactive oxygen species. *Free Radical Biology and Medicine* (2002).
- [35] Solano, F. Melanins: Skin Pigments and Much More -Types, Structural Models, Biological Functions, and Formation Routes. *New Journal of Science* (2014).
- [36] Haining, R. L. & Achat-Mendes, C. Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator. *Neural regeneration research* **12**, 372–375 (2017).

- [37] Cui, R. *et al.* Central role of p53 in the suntan response and pathologic hyperpigmentation. *Cell* **128**, 853–64 (2007).
- [38] Raposo, G. & Marks, M. S. Melanosomes - Dark organelles enlighten endosomal membrane transport (2007).
- [39] Raposo, G. & Marks, M. S. Melanosomes - Dark organelles enlighten endosomal membrane transport (2007).
- [40] Delevoye, C. Melanin transfer: The keratinocytes are more than gluttons (2014).
- [41] Boyd, K. P., Korf, B. R. & Theos, A. Neurofibromatosis type 1. *Journal of the American Academy of Dermatology* **61**, 1–16 (2009).
- [42] Schadendorf, D. *et al.* Melanoma. *The Lancet* **392**, 971–984 (2018).
- [43] Bevona, C. *et al.* Cutaneous Melanomas Associated with Nevi (2003).
- [44] Duffy, K. & Grossman, D. The dysplastic nevus: From historical perspective to management in the modern era: Part II. Molecular aspects and clinical management (2012).
- [45] Bataille, V. *et al.* Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: A case-control study. *British Journal of Cancer* **73**, 1605–1611 (1996).
- [46] Falchi, M. *et al.* Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. *Nature Genetics* **41**, 915–919 (2009).
- [47] Shain, A. H. & Bastian, B. C. From melanocytes to melanomas. *Nature Reviews Cancer* **16**, 345–358 (2016).
- [48] Grob, J. J. *et al.* Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. *Cancer* **66**, 387–95 (1990).
- [49] Shitara, D. *et al.* Nevus-Associated Melanomas. *American Journal of Clinical Pathology* **142**, 485–491 (2014).
- [50] Patton, E. E. *et al.* BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. *Current biology : CB* **15**, 249–54 (2005).
- [51] Law, M. H. *et al.* Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. *Nature Genetics* **47**, 987–995 (2015).

- [52] Rivers, J. K., Lewis, A. E. & Tate, B. J. Sunlight: A major factor associated with the development of melanocytic nevi in Australian schoolchildren. *Journal of the American Academy of Dermatology* (1994).
- [53] Dodd, A. T. *et al.* Melanocytic nevi and sun exposure in a cohort of Colorado children: Anatomic distribution and site-specific sunburn. *Cancer Epidemiology Biomarkers and Prevention* (2007).
- [54] Harrison, S. L., MacLennan, R. & Buettner, P. G. Sun exposure and the incidence of melanocytic nevi in young Australian children. *Cancer Epidemiology Biomarkers and Prevention* (2008).
- [55] Goldstein, A. M. & Tucker, M. A. Dysplastic nevi and melanoma. *Cancer Epidemiology Biomarkers and Prevention* (2013).
- [56] Tucker, M. A. *et al.* Clinically Recognized Dysplastic Nevi: A Central Risk Factor for Cutaneous Melanoma. *JAMA* **277**, 1439–1444 (1997).
- [57] Shain, A. H. *et al.* The Genetic Evolution of Melanoma from Precursor Lesions. *New England Journal of Medicine* **373**, 1926–1936 (2015).
- [58] Mocellin, S. & Nitti, D. Cutaneous Melanoma In Situ: Translational Evidence from a Large Population-Based Study. *The Oncologist* (2011).
- [59] Ribeiro-Silva, C., Vermeulen, W. & Lans, H. SWI/SNF: Complex complexes in genome stability and cancer (2019).
- [60] Reid, A. L. *et al.* Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. *The British journal of dermatology* **168**, 85–92 (2013).
- [61] Scott, J. F. & Gerstenblith, M. R. Melanoma of Unknown Primary. In *Noncutaneous Melanoma*, 99–116 (Codon Publications, 2018).
- [62] Smith Jr., J. L. & Stehlin Jr., J. S. Spontaneous regression of primary malignant melanomas with regional metastases. *Cancer* (1965).
- [63] Dutton-Regester, K. *et al.* Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. *Pigment Cell and Melanoma Research* (2013).

- [64] Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer (2007).
- [65] Wei, Z. & Liu, H. T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells (2002).
- [66] Roberts, P. J. & Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007).
- [67] Santarpia, L., Lippman, S. M. & El-Naggar, A. K. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy (2012).
- [68] McCain, J. The MAPK (ERK) pathway: Investigational combinations for the treatment of BRAF- mutated metastatic melanoma (2013).
- [69] Zhang, P. *et al.* Targeting CDK1 and MEK/ERK overcomes apoptotic resistance in BRAF-mutant human colorectal cancer. *Molecular Cancer Research* **16**, 378–389 (2018).
- [70] Leung, G. P. *et al.* Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma. *Molecular Cancer Research* **17**, 199–211 (2019).
- [71] Tannapfel, A. *et al.* Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. *Gut* (2003).
- [72] Cohen, Y. *et al.* BRAF Mutation in Papillary Thyroid Carcinoma. *JNCI Journal of the National Cancer Institute* **95**, 625–627 (2003).
- [73] Phipps, A. I. *et al.* BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* **21**, 1792–1798 (2012).
- [74] Singer, G. *et al.* Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma. *JNCI: Journal of the National Cancer Institute* **95**, 484–486 (2003).
- [75] Anglesio, M. S. *et al.* Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors. *Molecular Cancer Research* (2008).

- [76] Pratilas, C. A. *et al.* (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. *Proceedings of the National Academy of Sciences of the United States of America* **106**, 4519–4524 (2009).
- [77] Maurer, G., Tarkowski, B. & Baccarini, M. Raf kinases in cancer-roles and therapeutic opportunities (2011).
- [78] Muñoz-Couselo, E., García, J. S., Pérez-García, J. M., Cebrián, V. O. & Castán, J. C. Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. *Annals of translational medicine* **3**, 207 (2015).
- [79] Long, G. V. *et al.* Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. *Journal of Clinical Oncology* (2011).
- [80] Karoulia, Z., Gavathiotis, E. & Poulidakos, P. I. New perspectives for targeting RAF kinase in human cancer. *Nature Reviews Cancer* **17**, 676–691 (2017).
- [81] Harvey, J. J. An Unidentified Virus which causes the Rapid Production of Tumours in Mice. *Nature* **204**, 1104–1105 (1964).
- [82] Kirsten, W. H. & Mayer, L. A. Morphologic responses to a murine erythroblastosis virus. *Journal of the National Cancer Institute* **39**, 311–35 (1967).
- [83] Hall, A., Marshall, C. J., Spurr, N. K. & Weiss, R. A. Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. *Nature* **303**, 396–400.
- [84] Muñoz-Couselo, E., Adelantado, E. Z., Ortiz, C., García, J. S. & Perez-Garcia, J. NRAS-mutant melanoma: Current challenges and future prospect (2017).
- [85] Bos, J. L. ras Oncogenes in Human Cancer: A Review. *Cancer Research* **49**, 4682 LP – 4689 (1989).
- [86] Fedorenko, I. V., Gibney, G. T. & Smalley, K. S. M. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. *Oncogene* **32**, 3009–3018 (2013).
- [87] Pollock, P. M. *et al.* High frequency of BRAF mutations in nevi. *Nature genetics* **33**, 19–20 (2003).

- [88] Bauer, J., Curtin, J. A., Pinkel, D. & Bastian, B. C. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. *The Journal of investigative dermatology* **127**, 179–82 (2007).
- [89] Ranzani, M. *et al.* BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib (2015).
- [90] Kiuru, M. & Busam, K. J. The NF1 gene in tumor syndromes and melanoma. *Laboratory Investigation* **97**, 146–157 (2017).
- [91] Xue, A. *et al.* Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. *Nature Communications* **9** (2018).
- [92] Bishop, D. T. *et al.* Genome-wide association study identifies three loci associated with melanoma risk. *Nature Genetics* **41**, 920–925 (2009).
- [93] Landi, M. T. *et al.* Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. *Nature Genetics* **52**, 494–504 (2020).
- [94] Mavrakis, K. J. *et al.* Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. *Science* **351**, 1208–1213 (2016).
- [95] Shen, T. *et al.* Early-onset parkinson’s disease caused by PLA2G6 compound heterozygous mutation, a case report and literature review. *Frontiers in Neurology* **10**, 915 (2019).
- [96] Bose, A., Petsko, G. A. & Eliezer, D. Parkinson’s disease and melanoma: Co-occurrence and mechanisms (2018).
- [97] Visconti, A. *et al.* Genome-wide association study in 176,678 Europeans reveals genetic loci for tanning response to sun exposure. *Nature Communications* **9**, 1–7 (2018).
- [98] Hysi, P. G. *et al.* Genome-wide association meta-analysis of individuals of European ancestry identifies new loci explaining a substantial fraction of hair color variation and heritability. *Nature Genetics* **50**, 652–656 (2018).
- [99] Aoude, L. G., Wadt, K. A. W., Pritchard, A. L. & Hayward, N. K. Genetics of familial melanoma: 20 years after CDKN2A. *Pigment Cell & Melanoma Research* **28**, 148–160 (2015).

- [100] Serrano, M., Hannon, G. J. & Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature* (1993).
- [101] Li, J., Poi, M. J. & Tsai, M. D. Regulatory mechanisms of tumor suppressor P16INK4A and their relevance to cancer. *Biochemistry* (2011).
- [102] Honda, R. & Yasuda, H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. *The EMBO journal* **18**, 22–7 (1999).
- [103] Chong, S. S. *et al.* Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. *Nature Genetics* (1995).
- [104] Randerson-Moor, J. A. *et al.* A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. *Human molecular genetics* **10**, 55–62 (2001).
- [105] Måsbäck, A. *et al.* Clinical and histopathological features of malignant melanoma in germline CDKN2A mutation families. *Melanoma research* **12**, 549–57 (2002).
- [106] van der Rhee, J. I. *et al.* Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. *Journal of the American Academy of Dermatology* **65**, 281–288 (2011).
- [107] Zebary, A. *et al.* Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: A GenoMEL study (2014).
- [108] Staaf, J. *et al.* Primary Melanoma Tumors from CDKN2A Mutation Carriers Do Not Belong to a Distinct Molecular Subclass. *Journal of Investigative Dermatology* (2014).
- [109] Ghiorzo, P. *et al.* Characterization of Ligurian melanoma families and risk of occurrence of other neoplasia. *International Journal of Cancer* (1999).
- [110] Borg, Å. *et al.* High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. *Journal of the National Cancer Institute* (2000).
- [111] Lynch, H. T. *et al.* Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. *Cancer* **94**, 84–96 (2002).

- [112] Goldstein, A. M. Prospective risk of cancer in CDKN2A germline mutation carriers. *Journal of Medical Genetics* (2004).
- [113] McWilliams, R. R. *et al.* Prevalence of CDKN2A mutations in pancreatic cancer patients: Implications for genetic counseling. *European Journal of Human Genetics* (2011).
- [114] Sulong, S. *et al.* A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. *Blood* (2009).
- [115] Carrasco Salas, P. *et al.* The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia. *Pediatric hematology and oncology* **33**, 415–422 (2016).
- [116] Pacifico, A. & Leone, G. Role of p53 and CDKN2A inactivation in human squamous cell carcinomas (2007).
- [117] Saridaki, Z. *et al.* Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin. *The British journal of dermatology* **148**, 638–48 (2003).
- [118] Padhi, S. S. *et al.* Role of CDKN2A/p16 expression in the prognostication of oral squamous cell carcinoma. *Oral Oncology* (2017).
- [119] Zhou, C. *et al.* The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. *Cellular Physiology and Biochemistry* (2018).
- [120] Burri, N. *et al.* Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. *Laboratory investigation; a journal of technical methods and pathology* **81**, 217–29 (2001).
- [121] Schneider-Stock, R. *et al.* Hereditary p16-Leiden mutation in a patient with multiple head and neck tumors. *American journal of human genetics* **72**, 216–8 (2003).
- [122] Smigiel, R. *et al.* Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx. *Molecular carcinogenesis* **39**, 147–54 (2004).
- [123] Helgadottir, H. *et al.* Germline *CDKN2A* Mutation Status and Survival in Familial Melanoma Cases. *Journal of the National Cancer Institute* **108**, djw135 (2016).

- [124] Puntervoll, H. E. *et al.* Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. *Journal of medical genetics* **50**, 264–270 (2013).
- [125] Lu, W., Zhang, Y., Liu, D., Songyang, Z. & Wan, M. Telomeres-structure, function, and regulation (2013).
- [126] O’Sullivan, R. J. & Karlseder, J. Telomeres: Protecting chromosomes against genome instability (2010).
- [127] Robles-Espinoza, C. D., Velasco-Herrera, M. d. C., Hayward, N. K. & Adams, D. J. Telomere-regulating genes and the telomere interactome in familial cancers. *Molecular cancer research : MCR* **13**, 211–22 (2015).
- [128] Collins, K. & Mitchell, J. R. Telomerase in the human organism. *Oncogene* **21**, 564–579 (2002).
- [129] Nandakumar, J. & Cech, T. R. Finding the end: Recruitment of telomerase to telomeres (2013).
- [130] Bataille, V. *et al.* Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo. *Cancer Epidemiology Biomarkers and Prevention* **16**, 1499–1502 (2007).
- [131] Horn, S. *et al.* TERT Promoter Mutations in Familial and Sporadic Melanoma. *Science* **339**, 959–961 (2013).
- [132] Harland, M. *et al.* Germline TERT promoter mutations are rare in familial melanoma. *Familial Cancer* **15**, 139–144 (2016).
- [133] Huang, F. W. *et al.* Highly recurrent TERT promoter mutations in human melanoma. *Science* (2013).
- [134] Liu, X. *et al.* Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. *Cell cycle (Georgetown, Tex.)* **12**, 1637–1638 (2013).
- [135] Nonoguchi, N. *et al.* TERT promoter mutations in primary and secondary glioblastomas. *Acta Neuropathologica* (2013).
- [136] Liu, X. *et al.* Highly prevalent TERT promoter mutations in aggressive thyroid cancers. *Endocrine-related cancer* **20**, 603–610 (2013).

- [137] Tallet, A. *et al.* Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. *Oncogene* (2014).
- [138] Nault, J. C. *et al.* High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. *Nature communications* **4**, 2218 (2013).
- [139] Scott, G. A., Laughlin, T. S. & Rothberg, P. G. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* **27**, 516–23 (2014).
- [140] Heidenreich, B., Rachakonda, P. S., Hemminki, K. & Kumar, R. TERT promoter mutations in cancer development. *Current Opinion in Genetics & Development* **24**, 30–37 (2014).
- [141] De Lange, T. Shelterin: The protein complex that shapes and safeguards human telomeres (2005).
- [142] Li, B., Oestreich, S. & de Lange, T. Identification of Human Rap1: Implications for Telomere Evolution. *Cell* **101**, 471–483 (2000).
- [143] Robles-Espinoza, C. D. *et al.* POT1 loss-of-function variants predispose to familial melanoma. *Nature Genetics* **46**, 478–481 (2014).
- [144] Shi, J. *et al.* Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. *Nature genetics* **46**, 482–6 (2014).
- [145] Aoude, L. G. *et al.* Nonsense Mutations in the Shelterin Complex Genes ACD and TERF2IP in Familial Melanoma. *JNCI: Journal of the National Cancer Institute* **107** (2015).
- [146] Carbone, M. *et al.* BAP1 and cancer. *Nature Reviews Cancer* (2013).
- [147] Harbour, J. W. *et al.* Frequent mutation of BAP1 in metastasizing uveal melanomas. *Science* (2010).
- [148] Testa, J. R. *et al.* Germline BAP1 mutations predispose to malignant mesothelioma. *Nature genetics* **43**, 1022–1025 (2011).

- [149] Wiesner, T. *et al.* Germline mutations in BAP1 predispose to melanocytic tumors. *Nature Genetics* (2011).
- [150] Popova, T. *et al.* Germline BAP1 mutations predispose to renal cell carcinomas. *American journal of human genetics* **92**, 974–980 (2013).
- [151] Walpole, S. *et al.* Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide (2018).
- [152] O’Shea, S. J. *et al.* A population-based analysis of germline BAP1 mutations in melanoma. *Human molecular genetics* **26**, 717–728 (2017).
- [153] Arrangoiz, R. *et al.* Melanoma Review: Epidemiology, Risk Factors, Diagnosis and Staging. *Journal of Cancer Treatment and Research* **4**, 1–15 (2016).
- [154] Coleman, W. P. Acral Lentiginous Melanoma. *Archives of Dermatology* **116**, 773 (1980).
- [155] Rotte, A. & Bhandaru, M. Melanoma - Diagnosis, Subtypes and AJCC Stages. In *Immunotherapy of Melanoma* (2016).
- [156] Allen, A. C. & Spitz, S. Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis. *Cancer* **6**, 1–45 (1953).
- [157] Petersen, N. C., Bodenham, D. C. & Lloyd, O. C. Malignant melanomas of the skin. A study of the origin, development, aetiology, spread, treatment, and prognosis. *British journal of plastic surgery* **15**, 97–116 (1962).
- [158] McNeer, G. & Dasgupta, T. Prognosis in malignant melanoma. *Surgery* **56**, 512–8 (1964).
- [159] McGovern, V. J. The classification of melanoma and its relationship with prognosis. *Pathology* **2**, 85–98 (1970).
- [160] Tarhini, A., Lo, E. & Minor, D. R. Releasing the brake on the immune system: Ipilimumab in melanoma and other tumors (2010).
- [161] Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy (2012).
- [162] Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM (2013). [1303.3997](https://doi.org/10.1093/bioinformatics/btt320).

- [163] Poplin, R. *et al.* Scaling accurate genetic variant discovery to tens of thousands of samples. *bioRxiv* 201178 (2018).
- [164] McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biology* **17**, 122 (2016).
- [165] Ruffier, M. *et al.* Ensembl core software resources: storage and programmatic access for DNA sequence and genome annotation. *Database : the journal of biological databases and curation* **2017** (2017).
- [166] Auton, A. *et al.* A global reference for human genetic variation (2015).
- [167] Dudbridge, F. Power and Predictive Accuracy of Polygenic Risk Scores. *PLoS Genetics* **9** (2013).
- [168] Sacks, D. B. & McDonald, J. M. The Pathogenesis of Type II Diabetes Mellitus: A Polygenic Disease. *American Journal of Clinical Pathology* **105**, 149–156 (1996).
- [169] Rao, A. S. & Knowles, J. W. Polygenic risk scores in coronary artery disease. *Current opinion in cardiology* **34**, 435–440 (2019).
- [170] Purcell, S. M. *et al.* Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* **460**, 748–752 (2009).
- [171] Aly, M. *et al.* Polygenic risk score improves prostate cancer risk prediction: Results from the Stockholm-1 cohort study. *European Urology* **60**, 21–28 (2011).
- [172] Power, R. A. *et al.* Polygenic risk scores for schizophrenia and bipolar disorder predict creativity. *Nature Neuroscience* **18**, 953–955 (2015).
- [173] Saura, E., Eliades, P. J., Shannon, K., Stratigos, A. J. & Tsao, H. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. *Journal of the American Academy of Dermatology* **74**, 395–407; quiz 408–10 (2016).
- [174] Bishop, D. T. *et al.* Geographical variation in the penetrance of CDKN2A mutations for melanoma. *Journal of the National Cancer Institute* **94**, 894–903 (2002).
- [175] Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291 (2016).

- [176] Zhao, H. *et al.* CrossMap: a versatile tool for coordinate conversion between genome assemblies. *Bioinformatics* **30**, 1006–1007 (2014).
- [177] Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics (Oxford, England)* **25**, 2078–9 (2009).
- [178] Futreal, P. A. *et al.* A census of human cancer genes. *Nature Reviews Cancer* **4**, 177–183 (2004).
- [179] Riordan, J. R. *et al.* Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science (New York, N.Y.)* **245**, 1066–73 (1989).
- [180] MacDonald, M. E. M. *et al.* A polymorphic DNA marker genetically linked to Huntington's disease. *Nature* **306**, 234–8 (1993).
- [181] Nancarrow, D. J. *et al.* Confirmation of chromosome 9p linkage in familial melanoma. *American journal of human genetics* **53**, 936–42 (1993).
- [182] Easton, D. F., Bishop, D. T., Ford, D. & Crockford, G. P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. *Am J Hum Genet* **52**, 678–701 (1993).
- [183] Ford, D. *et al.* Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. *American journal of human genetics* **62**, 676–89 (1998).
- [184] Mehrgou, A. & Akouchekian, M. The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. *Medical journal of the Islamic Republic of Iran* **30**, 369 (2016).
- [185] Yandell, M. *et al.* A probabilistic disease-gene finder for personal genomes. *Genome Research* **21**, 1529–1542 (2011).
- [186] Hu, H. *et al.* A unified test of linkage analysis and rare-variant association for analysis of pedigree sequence data. *Nature biotechnology* **32**, 663–9 (2014).
- [187] Moore, C. *et al.* The INTERVAL trial to determine whether intervals between blood donations can be safely and acceptably decreased to optimise blood supply: study protocol for a randomised controlled trial. *Trials* **15**, 363 (2014).

- [188] Landrum, M. J. *et al.* ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic acids research* **42**, D980–5 (2014).
- [189] Helgadóttir, H. *et al.* Phenocopies in melanoma-prone families with germ-line CDKN2A mutations. *Genetics in Medicine* **20**, 1087–1090 (2018).
- [190] Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine* **17**, 405–423 (2015).
- [191] Khurana, E. *et al.* Role of non-coding sequence variants in cancer. *Nature Reviews Genetics* **17**, 93–108 (2016).
- [192] Wetterstrand, K. A. The Cost of Sequencing a Human Genome | NHGRI.
- [193] International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. *Nature* **409**, 860–921 (2001).
- [194] Wittkopp, P. J. & Kalay, G. Cis-regulatory elements: molecular mechanisms and evolutionary processes underlying divergence. *Nature Reviews Genetics* **13**, 59–69 (2012).
- [195] Heintzman, N. D. & Ren, B. Finding distal regulatory elements in the human genome. *Current opinion in genetics & development* **19**, 541–9 (2009).
- [196] Spielmann, M. & Mundlos, S. Looking beyond the genes: the role of non-coding variants in human disease. *Human Molecular Genetics* **25**, R157–R165 (2016).
- [197] Vaquerizas, J. M., Kummerfeld, S. K., Teichmann, S. A. & Luscombe, N. M. A census of human transcription factors: function, expression and evolution. *Nature Reviews Genetics* **10**, 252–263 (2009).
- [198] Schneider, T. D. & Stephens, R. M. Sequence logos: a new way to display consensus sequences. Tech. Rep. 20.
- [199] Khan, A. *et al.* JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. *Nucleic Acids Research* **46**, D260–D266 (2018).
- [200] Zhang, T. *et al.* SDHD Promoter Mutations Ablate GABP Transcription Factor Binding in Melanoma. *Cancer Research* **77**, 1649–1661 (2017).

- [201] Bond, G. L. *et al.* A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans. *Cell* **119**, 591–602 (2004).
- [202] Ruijs, M. W. G. *et al.* The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. *European Journal of Human Genetics* **15**, 110–114 (2007).
- [203] Haupt, S. *et al.* The role of MDM2 and MDM4 in breast cancer development and prevention. *Journal of molecular cell biology* **9**, 53–61 (2017).
- [204] Mansour, M. R. *et al.* An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. *Science* **346**, 1373–1377 (2014).
- [205] Feuk, L., Carson, A. R. & Scherer, S. W. Structural variation in the human genome. *Nature Reviews Genetics* **7**, 85–97 (2006).
- [206] Mills, R. E. *et al.* An initial map of insertion and deletion (INDEL) variation in the human genome. *Genome Research* **16**, 1182–1190 (2006).
- [207] Yi, K. & Ju, Y. S. Patterns and mechanisms of structural variations in human cancer. *Experimental & Molecular Medicine* **50**, 98 (2018).
- [208] Stephens, P. J. *et al.* Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell* **144**, 27–40 (2011).
- [209] Myers, R. H. Huntington's disease genetics. *NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics* **1**, 255–62 (2004).
- [210] Mccolgan, P. & Tabrizi, S. J. Huntington's disease: a clinical review. *European Journal of Neurology* **25**, 24–34 (2018).
- [211] Asim, A., Kumar, A., Muthuswamy, S., Jain, S. & Agarwal, S. Down syndrome: an insight of the disease. *Journal of biomedical science* **22**, 41 (2015).
- [212] Edwards, J. H., Harnden, D. G., Cameron, A. H., Crosse, V. M. & Wolff, O. H. A new trisomic syndrome. *The Lancet* **1**, 787–90 (1960).
- [213] Patau, K., Smith, D., Therman, E., Inhorn, S. & Wagner, H. Multiple congenital anomaly caused by an extra autosome. *The Lancet* **275**, 790–793 (1960).

- [214] Boveri, T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. *Journal of cell science* **121 Suppl**, 1–84 (2008).
- [215] Ratan, Z. A. *et al.* Application of Fluorescence In Situ Hybridization (FISH) Technique for the Detection of Genetic Aberration in Medical Science. *Cureus* **9**, e1325 (2017).
- [216] Kallioniemi, Visakorpi, Karhu, Pinkel & Kallioniemi. Gene Copy Number Analysis by Fluorescence in Situ Hybridization and Comparative Genomic Hybridization. *Methods (San Diego, Calif.)* **9**, 113–21 (1996).
- [217] Fan, X., Abbott, T. E., Larson, D. & Chen, K. BreakDancer - Identification of Genomic Structural Variation from Paired-End Read Mapping. *Current protocols in bioinformatics / editorial board, Andreas D. Baxevanis ... [et al.]* **2014** (2014).
- [218] Lindberg, M. R., Hall, I. M. & Quinlan, A. R. Population-based structural variation discovery with Hydra-Multi. *Bioinformatics* **31**, 1286–1289 (2015).
- [219] Zeitouni, B. *et al.* SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data. *Bioinformatics (Oxford, England)* **26**, 1895–6 (2010).
- [220] Wang, J. *et al.* CREST maps somatic structural variation in cancer genomes with base-pair resolution. *Nature Methods* **8**, 652–654 (2011).
- [221] Rausch, T. *et al.* DELLY: structural variant discovery by integrated paired-end and split-read analysis. *Bioinformatics (Oxford, England)* **28**, i333–i339 (2012).
- [222] Layer, R. M., Chiang, C., Quinlan, A. R. & Hall, I. M. LUMPY: a probabilistic framework for structural variant discovery. Tech. Rep. (2014).
- [223] Chaturvedi, P. *et al.* MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. *Cancer research* **68**, 2065–2070 (2008).
- [224] Kufe, D. W. Mucins in cancer: function, prognosis and therapy. *Nature reviews. Cancer* **9**, 874–885 (2009).
- [225] Shearer, R. F., Ionomou, M., Watts, C. K. & Saunders, D. N. Functional roles of the E3 Ubiquitin Ligase UBR5 in cancer (2015).
- [226] Waisberg, J. *et al.* Overexpression of the ITGAV gene is associated with progression and spread of colorectal cancer. *Anticancer research* **34**, 5599–607 (2014).

- [227] Cooper, C. R., Chay, C. H. & Pienta, K. J. The role of alpha(v)beta(3) in prostate cancer progression. *Neoplasia (New York, N.Y.)* **4**, 191–194 (2002).
- [228] Carbone, M. *et al.* Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s. *PLOS Genetics* **11**, e1005633 (2015).
- [229] Cheung, M. *et al.* Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. *Cancer Letters* **369**, 261–265 (2015).
- [230] Rahner, N. & Steinke, V. Hereditary cancer syndromes. *Deutsches Arzteblatt international* **105**, 706–14 (2008).
- [231] Lal, G. *et al.* Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. *Genes, Chromosomes and Cancer* **27**, 358–361 (2000).
- [232] Goldstein, A. M. *et al.* High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL (2006).
- [233] McKenzie, H. A. *et al.* Predicting functional significance of cancer-associated p16INK4a mutations in CDKN2A. *Human Mutation* **31**, 692–701 (2010).
- [234] Yokoyama, S. *et al.* A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. *Nature* **480**, 99–103 (2011).
- [235] Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K. & Linn, S. Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints. *Annual Review of Biochemistry* **73**, 39–85 (2004).
- [236] Chen, C.-F. *et al.* ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment. *Cell Reports* **18**, 2331–2342 (2017).
- [237] Oda, K. *et al.* p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53. *Cell* **102**, 849–862 (2000).
- [238] Benfodda, M. *et al.* Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma. *Genes, Chromosomes and Cancer* **57**, 294–303 (2018).
- [239] Sparks, J. L. *et al.* Human Exonuclease 5 Is a Novel Sliding Exonuclease Required for Genome Stability. *Journal of Biological Chemistry* **287**, 42773–42783 (2012).

- [240] Knijnenburg, T. A. *et al.* Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. *Cell Reports* **23**, 239–254.e6 (2018).
- [241] Dębniak, T. *et al.* Founder Mutations for Early Onset Melanoma as Revealed by Whole Exome Sequencing Suggests That This is Not Associated with the Increasing Incidence of Melanoma in Poland. *Cancer Research and Treatment* (2018).
- [242] Paumard-Hernández, B. *et al.* Whole exome sequencing identifies PLEC, EXON5 and DNAH7 as novel susceptibility genes in testicular cancer. *International Journal of Cancer* **143**, 1954–1962 (2018).
- [243] Rivera, M. N. *et al.* An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. *Science (New York, N.Y.)* **315**, 642–5 (2007).
- [244] Jenkins, Z. A. *et al.* Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. *Nature Genetics* **41**, 95–100 (2009).
- [245] Major, M. B. *et al.* Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. *Science (New York, N.Y.)* **316**, 1043–6 (2007).
- [246] Schatoff, E. M., Leach, B. I. & Dow, L. E. Wnt Signaling and Colorectal Cancer. *Current colorectal cancer reports* **13**, 101–110 (2017).
- [247] Luis, T. C., Ichii, M., Brugman, M. H., Kincade, P. & Staal, F. J. T. Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. *Leukemia* **26**, 414–421 (2012).
- [248] Pawlikowski, J. S. *et al.* Wnt signaling potentiates nevogenesis. *Proceedings of the National Academy of Sciences of the United States of America* **110**, 16009–14 (2013).
- [249] Lin, S. Y. *et al.* Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. *Proceedings of the National Academy of Sciences of the United States of America* **97**, 4262–6 (2000).
- [250] Hawkes, J. E. *et al.* Report of a novel OCA2 gene mutation and an investigation of OCA2 variants on melanoma risk in a familial melanoma pedigree. *Journal of Dermatological Science* **69**, 30–37 (2013).
- [251] Jay, J. J. & Brouwer, C. Lollipops in the Clinic: Information Dense Mutation Plots for Precision Medicine. *PLOS ONE* **11**, e0160519 (2016).

- [252] Etienne-Manneville, S. & Hall, A. Rho GTPases in cell biology. *Nature* **420**, 629–635 (2002).
- [253] Vega, F. M. & Ridley, A. J. Rho GTPases in cancer cell biology. *FEBS Letters* **582**, 2093–2101 (2008).
- [254] Porter, A. P., Papaioannou, A. & Malliri, A. Deregulation of Rho GTPases in cancer. *Small GTPases* **7**, 123–38 (2016).
- [255] Krauthammer, M. *et al.* Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. *Nature Genetics* **44**, 1006–1014 (2012).
- [256] Bustelo, X. R. Vav family exchange factors: an integrated regulatory and functional view. *Small GTPases* **5**, e973757 (2014).
- [257] Katzav, S. Vav1: A Dr. Jekyll and Mr. Hyde protein - good for the hematopoietic system, bad for cancer. *Oncotarget* **6** (2015).
- [258] Shalom, B., Farago, M., Pikarsky, E. & Katzav, S. Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes. *Oncogenesis* **7**, 80 (2018).
- [259] Robles-Valero, J. *et al.* A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia. *Cancer Cell* **32**, 608–623.e9 (2017).
- [260] Soussi, T. & Wiman, K. G. TP53: an oncogene in disguise. *Cell death and differentiation* **22**, 1239–49 (2015).
- [261] Chen, D. *et al.* SKI Activates Wnt/ β -Catenin Signaling in Human Melanoma. *Cancer Res.* **61**, 8074–8078 (2003).
- [262] Reed, J. A., Lin, Q., Chen, D., Mian, I. S. & Medrano, E. E. SKI pathways inducing progression of human melanoma. *Cancer and Metastasis Reviews* **24**, 265–272 (2005).
- [263] Chen, D. *et al.* SKI knockdown inhibits human melanoma tumor growth in vivo. *Pigment Cell & Melanoma Research* **22**, 761–772 (2009).
- [264] Bell, R. J. A. *et al.* Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. *Science (New York, N.Y.)* **348**, 1036–9 (2015).

- [265] Irby, R. B. & Yeatman, T. J. Role of Src expression and activation in human cancer. *Oncogene* **19**, 5636–5642 (2000).
- [266] Homsí, J., Cubitt, C. & Daud, A. The Src signaling pathway: a potential target in melanoma and other malignancies. *Expert Opinion on Therapeutic Targets* **11**, 91–100 (2007).
- [267] Homsí, J. *et al.* Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. *Melanoma Research* **19**, 167–175 (2009).
- [268] Puls, L. N., Eadens, M. & Messersmith, W. Current status of SRC inhibitors in solid tumor malignancies. *The oncologist* **16**, 566–78 (2011).
- [269] Ferguson, J., Arozarena, I., Ehrhardt, M. & Wellbrock, C. Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. *Oncogene* **32**, 86–96 (2013).
- [270] Awasthi, P., Foiani, M. & Kumar, A. ATM and ATR signaling at a glance. *Journal of Cell Science* **128**, 4255–4262 (2015).
- [271] Ainger, S. A., Jagirdar, K., Lee, K. J., Soyer, H. P. & Sturm, R. A. Skin Pigmentation Genetics for the Clinic. *Dermatology* **233**, 1–15 (2017).
- [272] Nathan, V. *et al.* Germline variants in oculocutaneous albinism genes and predisposition to familial cutaneous melanoma. *Pigment Cell & Melanoma Research* **32**, 854–863 (2019).
- [273] Haugh, A. M. *et al.* Genotypic and phenotypic features of BAP1 cancer syndrome: A report of 8 new families and review of cases in the literature. *JAMA Dermatology* **153**, 999–1006 (2017).
- [274] Potrony, M. *et al.* POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families. *British Journal of Dermatology* **181**, 105–113 (2019).